Article (Scientific journals)
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
Demoly, Pascal; Louis, Renaud; Soes-Petersen, Ulrik et al.
2009In Respiratory Medicine, 103 (11), p. 1623-32
Peer Reviewed verified by ORBi
 

Files


Full Text
Budesonide_formoterol maintenance and reliever therapy versus conventional best practice_Demoly_09_RespirMed.pdf
Author postprint (580.7 kB)
Download
Full Text Parts
Budesonide_formoterol maintenance and reliever therapy versus conventional best practice_Demoly_09_RespirMed.pdf
Publisher postprint (580.7 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta(2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP). This pooled analysis of six 6-month, randomized, open-label studies examined asthma control and exacerbation risk in asthmatics (aged> or =12 years). Patients (N=7855) symptomatic on inhaled corticosteroids (ICS) or stable/symptomatic on ICS/long-acting beta(2)-agonists (LABA) received budesonide/formoterol maintenance and reliever therapy (160/4.5microg bid and as needed) or CBP (ICS or ICS/LABA+/-other agents at an approved dose plus as-needed SABA). Overall asthma control was assessed comparing the incidence of exacerbations and levels of asthma control using the asthma control questionnaire (ACQ). Budesonide/formoterol maintenance and reliever therapy did not significantly reduce time to first severe exacerbation (primary variable) versus CBP (P=0.062). However, patients in this group experienced 15% fewer exacerbations (0.20 versus 0.24/patient/year; P=0.021) and used 27% less ICS (P<0.0001). Odds of remaining well controlled (ACQ< or =0.75) over 6 months were higher with budesonide/formoterol maintenance and reliever therapy versus CBP (45% versus 41%, odds ratio [OR] 1.29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Demoly, Pascal
Louis, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Soes-Petersen, Ulrik
Naya, Ian
Carlsheimer, Asa
Worth, Heinrich
Almeida, Joao
Sears, Malcolm R
Language :
English
Title :
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
Publication date :
2009
Journal title :
Respiratory Medicine
ISSN :
0954-6111
eISSN :
1532-3064
Publisher :
Elsevier, Oxford, United Kingdom
Volume :
103
Issue :
11
Pages :
1623-32
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 15 January 2010

Statistics


Number of views
97 (3 by ULiège)
Number of downloads
170 (1 by ULiège)

Scopus citations®
 
44
Scopus citations®
without self-citations
40
OpenCitations
 
37

Bibliography


Similar publications



Contact ORBi